Diffuse Cutaneous Systemic Sclerosis

OnabotulinumtoxinA offers short-term relief to patients suffering from scleroderma/systemic sclerosis-induced microstomia, according to a study.

Managing oral, ocular and cutaneous complications is critical to optimizing outcomes in conditions ranging from Sjögren’s syndrome to juvenile dermatomyositis, according to a presenter who offered a cross-section of “pearls and myths” at ACR Convergence 2021.

Although lenabasum failed to meet its efficacy endpoint in a trial of patients with diffuse cutaneous systemic sclerosis, a post-hoc analysis suggests an impact on forced vital capacity, according to a speaker at the EULAR 2021 Congress.